RxDoctor Payments Data

Kelsey Rutter, APRN

Family · Irmo, SCNPI 1518686674

Payments from drug & device makers

$3,228in general payments, 2019–2025

Across 165 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$413
  • Otsuka America Pharmaceutical, Inc.$336
  • Sumitomo Pharma America, Inc.$195
  • Lilly USA, LLC$177
  • Axsome Therapeutics, Inc.$154
  • Exact Sciences$149
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$3,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,228 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$54,742
Medicare patients
262
Services billed
1,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$16,982
MounjaroTirzepatide15$15,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,830
OzempicSemaglutide11$10,174
Albuterol Sulfate HfaAlbuterol Sulfate20$476
Fluticasone Propionate40$333
Rosuvastatin Calcium17$322
Nifedipine ErNifedipine12$318
Duloxetine Hcl18$306
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$289
Doxycycline Hyclate25$237
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip16$226
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$209
Methylprednisolone26$199
Pravastatin Sodium15$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$45$16,98217 claims
Lilly USA, LLCMounjaro$177$15,92715 claims
GSKTrelegy Ellipta$38$13,83022 claims
Novo NordiskOzempic$111$10,17411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Irmo

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →